Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 386


Phenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines.

Martowicz A, Spizzo G, Gastl G, Untergasser G.

BMC Cancer. 2012 Oct 30;12:501. doi: 10.1186/1471-2407-12-501.


EpCAM overexpression prolongs proliferative capacity of primary human breast epithelial cells and supports hyperplastic growth.

Martowicz A, Rainer J, Lelong J, Spizzo G, Gastl G, Untergasser G.

Mol Cancer. 2013 Jun 10;12:56. doi: 10.1186/1476-4598-12-56.


EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy.

Osta WA, Chen Y, Mikhitarian K, Mitas M, Salem M, Hannun YA, Cole DJ, Gillanders WE.

Cancer Res. 2004 Aug 15;64(16):5818-24.


Activator protein 1 (AP-1) contributes to EpCAM-dependent breast cancer invasion.

Sankpal NV, Mayfield JD, Willman MW, Fleming TP, Gillanders WE.

Breast Cancer Res. 2011;13(6):R124. doi: 10.1186/bcr3070. Epub 2011 Dec 1.


Transient but not stable ZEB1 knockdown dramatically inhibits growth of malignant pleural mesothelioma cells.

Horio M, Sato M, Takeyama Y, Elshazley M, Yamashita R, Hase T, Yoshida K, Usami N, Yokoi K, Sekido Y, Kondo M, Toyokuni S, Gazdar AF, Minna JD, Hasegawa Y.

Ann Surg Oncol. 2012 Jul;19 Suppl 3:S634-45. doi: 10.1245/s10434-011-2142-0. Epub 2011 Nov 16.


Effects of EpCAM overexpression on human breast cancer cell lines.

Gostner JM, Fong D, Wrulich OA, Lehne F, Zitt M, Hermann M, Krobitsch S, Martowicz A, Gastl G, Spizzo G.

BMC Cancer. 2011 Jan 31;11:45. doi: 10.1186/1471-2407-11-45.


Clinicopathologic significance of EpCAM expression in squamous cell carcinoma of the tongue and its possibility as a potential target for tongue cancer gene therapy.

Yanamoto S, Kawasaki G, Yoshitomi I, Iwamoto T, Hirata K, Mizuno A.

Oral Oncol. 2007 Oct;43(9):869-77. Epub 2007 Jan 4.


By inhibiting Ras/Raf/ERK and MMP-9, knockdown of EpCAM inhibits breast cancer cell growth and metastasis.

Gao J, Liu X, Yang F, Liu T, Yan Q, Yang X.

Oncotarget. 2015 Sep 29;6(29):27187-98. doi: 10.18632/oncotarget.4551.


Context-dependent adaption of EpCAM expression in early systemic esophageal cancer.

Driemel C, Kremling H, Schumacher S, Will D, Wolters J, Lindenlauf N, Mack B, Baldus SA, Hoya V, Pietsch JM, Panagiotidou P, Raba K, Vay C, Vallböhmer D, Harréus U, Knoefel WT, Stoecklein NH, Gires O.

Oncogene. 2014 Oct 9;33(41):4904-15. doi: 10.1038/onc.2013.441. Epub 2013 Oct 21.


EpCAM, a potential therapeutic target for esophageal squamous cell carcinoma.

Matsuda T, Takeuchi H, Matsuda S, Hiraiwa K, Miyasho T, Okamoto M, Kawasako K, Nakamura R, Takahashi T, Wada N, Kawakubo H, Saikawa Y, Omori T, Kitagawa Y.

Ann Surg Oncol. 2014 Jun;21 Suppl 3:S356-64. doi: 10.1245/s10434-014-3579-8. Epub 2014 Feb 25.


MTA1-upregulated EpCAM is associated with metastatic behaviors and poor prognosis in lung cancer.

Zhou N, Wang H, Liu H, Xue H, Lin F, Meng X, Liang A, Zhao Z, Liu Y, Qian H.

J Exp Clin Cancer Res. 2015 Dec 23;34:157. doi: 10.1186/s13046-015-0263-1.


Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway.

Ni J, Cozzi P, Hao J, Beretov J, Chang L, Duan W, Shigdar S, Delprado W, Graham P, Bucci J, Kearsley J, Li Y.

Int J Biochem Cell Biol. 2013 Dec;45(12):2736-48. doi: 10.1016/j.biocel.2013.09.008. Epub 2013 Sep 25.


EpCAM modulates NF-κB signaling and interleukin-8 expression in breast cancer.

Sankpal NV, Fleming TP, Gillanders WE.

Mol Cancer Res. 2013 Apr;11(4):418-26. doi: 10.1158/1541-7786.MCR-12-0518. Epub 2013 Feb 1.


Epithelial-to-mesenchymal transition induced by TGF-β1 is mediated by AP1-dependent EpCAM expression in MCF-7 cells.

Gao J, Yan Q, Wang J, Liu S, Yang X.

J Cell Physiol. 2015 Apr;230(4):775-82. doi: 10.1002/jcp.24802.


Pancreatic cancer stem-like cells display aggressive behavior mediated via activation of FoxQ1.

Bao B, Azmi AS, Aboukameel A, Ahmad A, Bolling-Fischer A, Sethi S, Ali S, Li Y, Kong D, Banerjee S, Back J, Sarkar FH.

J Biol Chem. 2014 May 23;289(21):14520-33. doi: 10.1074/jbc.M113.532887. Epub 2014 Apr 9.


Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.

Richter CE, Cocco E, Bellone S, Bellone M, Casagrande F, Todeschini P, Rüttinger D, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

Int J Gynecol Cancer. 2010 Dec;20(9):1440-7.


EpCAM Aptamer-siRNA Chimera Targets and Regress Epithelial Cancer.

Subramanian N, Kanwar JR, Kanwar RK, Sreemanthula J, Biswas J, Khetan V, Krishnakumar S.

PLoS One. 2015 Jul 15;10(7):e0132407. doi: 10.1371/journal.pone.0132407. eCollection 2015.


High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion.

Lehtinen L, Ketola K, Mäkelä R, Mpindi JP, Viitala M, Kallioniemi O, Iljin K.

Oncotarget. 2013 Jan;4(1):48-63.


Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.

Amoury M, Kolberg K, Pham AT, Hristodorov D, Mladenov R, Di Fiore S, Helfrich W, Kiessling F, Fischer R, Pardo A, Thepen T, Hussain AF, Nachreiner T, Barth S.

Cancer Lett. 2016 Mar 28;372(2):201-9. doi: 10.1016/j.canlet.2016.01.027. Epub 2016 Jan 21.


Uncoupling of the ERα regulated morphological phenotype from the cancer stem cell phenotype in human breast cancer cell lines.

Gadalla SE, Alexandraki A, Lindström MS, Nistér M, Ericsson C.

Biochem Biophys Res Commun. 2011 Feb 25;405(4):581-7. doi: 10.1016/j.bbrc.2011.01.072. Epub 2011 Jan 23.


Supplemental Content

Support Center